February 14, 2023 11:21 AM EST

Cell therapy biotech nabs Series A; Metagenome startup snags $77M round

Kyle LaHucik

Senior Reporter

A cancer cell therapy biotech has reeled in about $20 million to push forward its ongoing Phase I.

Alloplex Biotherapeutics has secured about $20 million of an estimated $25 million round, per SEC paperwork. CEO Frank Borriello posted to LinkedIn two months ago noting the company would look to close a Series A by Jan. 27. Borriello, a former VP at Baxalta, formed the US-Australian biotech in 2016.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Cell therapy biotech nabs Series A; Metagenome startup snags $77M round

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Supreme Court weighs in on Purdue Pharma's bankruptcy, with an eye toward opioid victims

Roche's BTK inhibitor put on partial hold over concerns about potential liver injury

Novartis unveils new brand identity after Sandoz spinoff

Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test

Early prediction of outcomes in DLBCL clinical trials through MRD testing

Cell ther­a­py biotech nabs Se­ries A; Metagenome start­up snags $77M round

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

Supreme Court weighs in on Pur­due Phar­ma's bank­rupt­cy, with an eye to­ward opi­oid vic­tims

Roche's BTK in­hibitor put on par­tial hold over con­cerns about po­ten­tial liv­er in­jury

No­var­tis un­veils new brand iden­ti­ty af­ter San­doz spin­off

Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

Cell therapy biotech nabs Series A; Metagenome startup snags $77M round

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Supreme Court weighs in on Purdue Pharma's bankruptcy, with an eye toward opioid victims

Roche's BTK inhibitor put on partial hold over concerns about potential liver injury

Novartis unveils new brand identity after Sandoz spinoff

Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test

Early prediction of outcomes in DLBCL clinical trials through MRD testing